Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > 4-maleimido-2,2,6,6-tetramethylpiperidinooxyl

4-maleimido-2,2,6,6-tetramethylpiperidinooxyl

Discover the power of PubCompare.ai in enhancing your research accuracy and reproducibility.
Our AI-driven platform helps you locate the best protocols, products, and preprints related to 4-maleimido-2,2,6,6-tetramethylpiperidinooxyl.
With our advanced comparison tools, you can easily identify the most reliable and effective methods, saving you time and ensuring the sucsess of your experiments.
Experience the future of research with PubCompare.ai.

Most cited protocols related to «4-maleimido-2,2,6,6-tetramethylpiperidinooxyl»

1
Validating IBD-Control Questionnaire in Clinical Practice
The prospective validation study recruited patients at the investigating centre, a university hospital serving a population of approximately 330 000 people with an established secondary care IBD service providing outpatient and inpatient medical and surgical care.23 (link) Patients were recruited during routine visits to the outpatient clinics prior to consultation with the doctor or specialist nurse, during other treatment-related visits (eg, azathioprine monitoring clinic or infusion visit for biologics) or at the time of admission for inpatient care. Inclusion criteria specified a confirmed diagnosis of IBD on the basis of clinical, endoscopic, radiological and/or histological criteria with disease duration of at least 6 months. Exclusion criteria specified non-English speaking subjects, cognitive impairment or serious active psychiatric disease.
After informed consent, the patients completed the IBD-Control questionnaire and were then asked to complete a questionnaire pack comprising a disease-specific QoL questionnaire (the UK-IBD-QoL),16 (link)
17 (link) a generic health status instrument (EuroQol, EQ-5D-3L),24 (link) and the Hospital Anxiety and Depression Scale.25 (link) The research team undertook a simultaneous assessment of current disease activity, using the Harvey-Bradshaw Index (HBI) for CD 5 (link) and the Simple Clinical Colitis Activity Index (SCCAI) for UC.6 (link) The research team and clinicians were blinded to the results of patient-completed questionnaires.
Where the study visit was taking place at a scheduled clinical review (eg, outpatient attendance), the treating clinician or specialist nurse was asked to complete a questionnaire at the end of the consultation to indicate the current state of IBD (Global Physician Assessment) using a categorical scale (remission, mild, moderate or severe), blinded to patient surveys. All treatment decisions were recorded, capturing whether new therapies were started, existing drug doses changed, therapies discontinued or surgery recommended. The research team reviewed the hospital case records and clinical information systems to extract background clinical information regarding diagnosis, duration of disease, previous hospitalisation and surgery, disease extent, presence of stoma or perianal fistulae, major comorbid illness and current therapy for their IBD.
Bodger K., Ormerod C., Shackcloth D, & Harrison M. (2013). Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-Control questionnaire. Gut, 63(7), 1092-1102.
Publication 2013
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl Anxiety Azathioprine Biological Factors Colitis concomitant disease Diagnosis Disorders, Cognitive Endoscopy Fistula Generic Drugs Inpatient Mental Disorders Nurses Operative Surgical Procedures Outpatients Patients Pharmaceutical Preparations Physicians Secondary Care Surgical Stoma Therapeutics X-Rays, Diagnostic
2
Genetic Overlap Across Allergic Diseases
By combining information from asthma, hay fever and eczema in the
case-control definition used in our GWAS, we expected our study design to
improve power to identify risk variants shared between, but not specific to any
of, the three diseases 6 (link). To understand if
the associations discovered in our GWAS were indeed likely to represent risk
factors shared across allergic diseases, we took advantage of the observation
that not all affected individuals report allergic co-morbidities 1 (link),22 (link),23 (link), and compared allele
frequencies between three groups of adults: asthma-only cases
(n=12,268), hay fever-only cases
(n=33,305) and eczema-only cases (n=6,276).
The studies that contributed to this analysis are indicated in Supplementary Table 1 and
described in detail in the Supplementary Note. We performed three sets of association analyses
contrasting three non-overlapping groups of individuals: asthma-only (g1) vs.
hay fever-only (g2); asthma-only (g1) vs. eczema-only (g3); and hay fever-only
(g2) vs. eczema-only (g3). These analyses are statistically independent from the
case-control analysis carried out as part of the GWAS, which facilitates
interpretation of the results. For a given sentinel SNP, results from these
analyses indicate if the risk allele is more (odds ratio [OR] >1) or less
(OR<1) common in e.g. group 1 (g1) when compared to group 2 (g2). For
example, if a SNP contributed similarly to the risks of asthma and hay fever but
not eczema, then one would expect an OR~1 in the asthma-only vs. hay
fever-only comparison, but an OR>1 in the asthma vs. eczema and hay fever vs.
eczema analyses. The significance threshold for these analyses was set at
1.2x10-4, which corresponds to a Bonferroni correction for the
136 SNPs and three sets of analyses performed (i.e.
P<0.05/(136x3)).
Ferreira M.A., Vonk J.M., Baurecht H., Marenholz I., Tian C., Hoffman J.D., Helmer Q., Tillander A., Ullemar V., van Dongen J., Lu Y., Rüschendorf F., Esparza-Gordillo J., Medway C.W., Mountjoy E., Burrows K., Hummel O., Grosche S., Brumpton B.M., Witte J.S., Hottenga J.J., Willemsen G., Zheng J., Rodríguez E., Hotze M., Franke A., Revez J.A., Beesley J., Matheson M.C., Dharmage S.C., Bain L.M., Fritsche L.G., Gabrielsen M.E., Balliu B., Nielsen J.B., Zhou W., Hveem K., Langhammer A., Holmen O.L., Løset M., Abecasis G.R., Willer C.J., Arnold A., Homuth G., Schmidt C.O., Thompson P.J., Martin N.G., Duffy D.L., Novak N., Schulz H., Karrasch S., Gieger C., Strauch K., Melles R.B., Hinds D.A., Hübner N., Weidinger S., Magnusson P.K., Jansen R., Jorgenson E., Lee Y.A., Boomsma D.I., Almqvist C., Karlsson R., Koppelman G.H, & Paternoster L. (2017). Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. Nature genetics, 49(12), 1752-1757.
Publication 2017
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl Adult Alleles Asthma Eczema Fever, Hay Genome-Wide Association Study Hypersensitivity Single Nucleotide Polymorphism
3
Algorithm for Garbage Code Redistribution
The algorithm for garbage code redistribution was developed based on the GBD 2010 and 2013 Study methodologies (8 (link)16 (link)), the New Zealand Burden of Disease Study report (9 ), and the Korean Standard Classification of Disease-6 (Fig. 1) (17 ). Furthermore, expert opinions were considered for a few diseases. The specialists of each disease examined the appropriateness of the distribution rate, and as a result, the final garbage code list included 84 items. The 2010–2012 data on CoD statistics from the Statistics Korea were used to calculate the number of deaths, and an age-specific life table from Statistics Korea was used to calculate the standard life expectancy (4 ). CoD was classified into target cause, which is target of redistributed garbage code, and garbage code deaths (8 (link)11 ).
To apply the developed algorithm, the 2010–2012 CoD data from the Statistics Korea were utilized to calculate age- and sex-specific death rates for each disease in a certain period of time. Then the number of deaths within each of the 84 garbage codes was determined. Each garbage code death was then distributed to a relevant target cause based on each garbage code proportion. The distributed garbage code deaths were then redistributed again based on the sex- and age-specific rates of each target CoD. The total number of target cause death is the sum of original death due to target cause and sum of redistributed garbage code death.
Lee Y.R., Kim Y.A., Park S.Y., Oh C.M., Kim Y.E, & Oh I.H. (2016). Application of a Modified Garbage Code Algorithm to Estimate Cause-Specific Mortality and Years of Life Lost in Korea. Journal of Korean Medical Science, 31(Suppl 2), S121-S128.
Publication 2016
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl Garbage Koreans Physiological Sexual Disorders Specialists
4
Comprehensive Respiratory Health Questionnaire
The study consisted of a booklet containing the OLIN-Q followed by the GA2LEN-Q. The OLIN-Q has been used in many studies in the Nordic and the Baltic countries, prominently the FinEsS (Finland, Estonia, Sweden) studies, comparative studies of airway diseases 6 (link), 17 (link), 18 (link)). It was developed from the British Medical Research Council Q (BMRC-Q). The OLIN-Q contains questions on asthma, rhinitis, chronic bronchitis/COPD/emphysema, respiratory symptoms, use of asthma medication and possible determinants of disease, such as smoking habit, occupation and family history of disease. The OLIN-Q and variants of it (19 (link)) have been validated against physiological variables including bronchial hyperresponsiveness (12 (link), 20 (link)). To this Q, detailed questions about occupation, occupational exposure, socio-economic conditions and health status were added. The Swedish version of the GA2LEN-Q is a variant of the ECRHS-Q (13 (link), 21 (link)) with additional questions concerning mainly rhinitis, chronic sinusitis and eczema. Questions on rhinitis and sinusitis in the GA2LEN-Q originate from the Allergic Rhinitis and its Impact on Asthma initiative (21 (link)).
Ekerljung L., Rönmark E., Lötvall J., Wennergren G., Torén K, & Lundbäck B. (2013). Questionnaire layout and wording influence prevalence and risk estimates of respiratory symptoms in a population cohort. The Clinical Respiratory Journal, 7(1), 53-63.
Publication 2013
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl Asthma Bronchial Hyperreactivity Bronchitis, Chronic Chronic Obstructive Airway Disease Eczema Emphysema Occupational Exposure Pharmaceutical Preparations physiology Rhinitis Rhinitis, Allergic Signs and Symptoms, Respiratory Sinusitis
5
NSCLC Immunotherapy Response Evaluation
The study cohort of NSCLC patients was established by recruiting patients from Yonsei Cancer Center, Seoul, Korea. Eighteen patients were in the discovery cohort, whereas 56 were in the validation cohort. Each patient was administered either nivolumab or pembrolizumab. Patients were classified as responders if they showed partial response (PR) or stable disease (SD) for >6 months according to Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.120 (link). Patients who showed progressive disease (PD) or SD for ≤6 months were classified as non-responders by RECIST ver. 1.121 (link). Computed tomography (CT) studies were independently read by radiologists. All tumor samples were obtained from patients before immunotherapy.
Cho J.W., Hong M.H., Ha S.J., Kim Y.J., Cho B.C., Lee I, & Kim H.R. (2020). Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer. Experimental & Molecular Medicine, 52(9), 1550-1563.
Publication 2020
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl Immunotherapy Malignant Neoplasms Neoplasms Nivolumab Non-Small Cell Lung Carcinoma Patients pembrolizumab Radiologist X-Ray Computed Tomography

Most recents protocols related to «4-maleimido-2,2,6,6-tetramethylpiperidinooxyl»

1
Intracranial Progression-Free Survival
The primary end point was intracranial progression-free survival (iPFS) with secondary end points of extracranial progression-free survival (ePFS) and overall survival (OS). Objective intracranial response rate was defined as the proportion of patients who achieved CR or PR. Clinical benefit rate was the proportion of patients with stable disease for ≥6 months or achieved CR or PR among all evaluable patients. Patients who had stable disease for ≥6 months were considered unevaluable for that measure.
Tringale K.R., Reiner A.S., Sehgal R.R., Panageas K., Betof Warner A.S., Postow M.A, & Moss N.S. (2023). Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure. CNS Oncology, 12(1), CNS93.
Publication 2023
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl Patients
2
Antiangiogenic Agents and PD-1 Inhibitors for Metastatic Soft Tissue Sarcoma
We retrospectively analyzed patients with metastatic STS treated with antiangiogenic agents plus PD-1 inhibitors in Henan Cancer Hospital, the Fifth Affiliated Hospital of Zhengzhou University, and Henan Provincial People’s Hospital between June 2019 and May 2022. This study complied with the principles of Helsinki, met the requirements of the ethics committee and was approved by the ethics committees of each institute. All participants provided written informed consent before treatment.
Patients were included according to the main criteria: 1. Age 18 to 70; 2. The performance status of Eastern Tumor Cooperative Group (ECOG) is 0-2; 3. The pathological diagnosis included ASPS, UPS, synovium, LMS, epithelioid sarcoma (ES), fibrosarcoma, etc. 4. At least one measure based on the Response Evaluation Criteria for Solid Tumors (RECIST) 1.1; 5. Complete medical history and follow-up records; 6. Not eligible for or refusing first-line chemotherapy; and 7. Progressive disease within 6 months before combination treatment. Patients were excluded if they presented contraindications of antiangiogenic agents and/or PD-1 inhibitors including coagulation dysfunction, active asthma, etc.
Liu Z., Wang X., Wang J., Zhang P., Li C., Wang B., Gao S., Liu O, & Yao W. (2023). The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study. Frontiers in Oncology, 13, 1124517.
Publication 2023
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl Angiogenesis Inhibitors ASIP protein, human Asthma Coagulation, Blood Diagnosis Electrocorticography Ethics Committees Fibrosarcoma Neoplasms Patients Pharmacotherapy Programmed Cell Death Protein 1 Inhibitor Sarcoma, Epithelioid Synovial Membrane
3
Systemic Lupus Erythematosus Immune Profiling
The study population comprised 14 healthy individuals and 38 SLE subjects divided into the following groups: 27 inactive lupus (SLEDAI ≤6), 11 with active disease (SLEDAI >6) were recruited from the department of Immunology and Rheumatology of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. All SLE patients fulfilled ACR/SLICC 2012 classification criteria (28 (link)), and disease activity was addressed by the SLE disease activity index (SLEDAI). We excluded subjects with ongoing acute or chronic infections (i.e., HIV or viral hepatitis), pregnancy, and patients with a diagnosis of other concomitant autoimmune diseases except for antiphospholipid (aPL) syndrome. None of the study participants received any B cell-depleting or other biological therapies. This study was approved by the Institutional Ethics and Research Committees of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (Ref. 2306). The patients/participants provided their written informed consent to participate prior to inclusion in the study. Demographic and Clinical characteristics of the study population are depicted in Table 1.
Romero-Ramírez S., Sosa-Hernández V.A., Cervantes-Díaz R., Carrillo-Vázquez D.A., Meza-Sánchez D.E., Núñez-Álvarez C., Torres-Ruiz J., Gómez-Martín D, & Maravillas-Montero J.L. (2023). Salivary IgA subtypes as novel disease biomarkers in systemic lupus erythematosus. Frontiers in Immunology, 14, 1080154.
Publication 2023
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl Antiphospholipid Syndrome Autoimmune Diseases B-Lymphocytes Chronic Infection Diagnosis Hepatitis Viruses Lupus Vulgaris Patients Pregnancy Therapies, Biological
4
TMB and PD-L1 Predict ICB Response in Cancers
The TMB and PD-L1 expression level were widely regarded as predictors of the efficacy of ICB treatment in clinical practice. We calculated the TMB of each patient in the TCGA cohort according to somatic mutation data and compared the TMB value between different TMGS groups. Besides, ROC curves were generated to evaluate the ICB response prediction ability of TMB, PD-L1, and TMGS in PDAC patients. Furthermore, each patient's Tumor Immune Dysfunction and Exclusion (TIDE) score was calculated from the TIDE website (http://tide.dfci.harvard.edu/). The TIDE score was developed to predict anti-PD1 and anti-CTLA4 responses across several melanoma datasets and a limited dataset of NSCLC36 (link). In prospective clinical trials, the TIDE score will be of great significance in ICB response prediction36 (link).
We also investigated the ICB response predictive ability and risk stratification ability of TMGS in mUC patients (IMvigor210 cohort) and adNSCLC patients (GSE135222 series) who received anti-PD-L1/ anti-PD-1 therapy. The IMvigor210 cohort records RNA-seq data, OS, follow-up information, and treatment response information of 348 mUC cases treated with anti-PD-L1 agents. According to patients’ response status, they were stratified into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD), respectively. GSE135222 series stores the expression matrix, PFS, survival status, and ICB response of 27 adNSCLC patients. Accordingly, the efficacy was defined as durable clinical benefit [DCB: CR, PR, and SD lasting for ≥ 6 months] or no durable benefit [NDB: PD or SD that lasted < 6 months]37 (link). We also applied The R software, “pRRophetic” package to forecast the semi-inhibitory concentration (IC50) values of commonly used chemotherapeutic agents for every PDAC case from different TMGS groups38 (link). Ultimately, the Drug Gene Interaction Database (DGIdb) (https://dgidb.genome.wustl.edu/)39 (link) was used to find candidate drugs corresponding to the prognostic TMGs, with the PubChem website (https://pubchem.ncbi.nlm.nih.gov/) being exploited to display their 3D structures40 (link).
Zheng H., Li Y., Zhao Y, & Jiang A. (2023). Single-cell and bulk RNA sequencing identifies T cell marker genes score to predict the prognosis of pancreatic ductal adenocarcinoma. Scientific Reports, 13, 3684.
Publication 2023
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl Anophthalmia with pulmonary hypoplasia Anti-Anxiety Agents Antineoplastic Agents Betaine CTLA4 protein, human Diploid Cell Drug Interactions Genes Genome Immune System Diseases Melanoma Mutation Neoplasms Patients Pharmaceutical Preparations Psychological Inhibition RNA-Seq
5
Apatinib and Sintilimab with Chemotherapy
Apatinib was given as a fixed dose of 250 mg once a day, within 30 min after breakfast. Sintilimab was given within 60 min before chemotherapy by intravenous infusion of a fixed dose of 200 mg every 3 weeks. Antiemetic drugs were given by intravenous infusion 30 min before chemotherapy with either irinotecan (150 mg/m2, 90-minute intravenous infusion once every 2 weeks) or paclitaxel (150 mg/m2, 3-hour intravenous infusion once every 3 weeks). Considering that compared with monotherapy combination may increase the risk of toxic reactions, and chemotherapy is more important to play an immunomodulatory role in the combination therapy, the dose of chemotherapy drugs in this study was lowered compared with the conventional dose. Prophylactic atropine was given before the next irinotecan infusion treatment for patients with acute cholinergic syndrome. To prevent allergic reaction, 10 mg of oral dexamethasone was given 12 and 6 h before paclitaxel administration, and 400 mg of intravenous cimetidine and 50 mg of intramuscular diphenhydramine were given 30 min before paclitaxel administration. An intravenous infusion of sintilimab every 3 weeks is considered one cycle. Apatinib and sintilimab were continued until the disease progressed or became intolerable or up to 2 years, and the chemotherapy drug irinotecan or paclitaxel was continued until the disease progression, intolerable toxicity, or up to 6 months. If adverse events occurred during treatment, symptomatic and supportive treatments were given according to clinical protocol. Immune-related adverse events were treated with reference to the NCCN immune-related toxicity management guidelines. Blood or urine laboratory tests such as routine blood parameters, blood biochemistry, heart function, routine urinalysis, and thyroid function were regularly performed according to clinical protocol. Contrast-enhanced computed tomography of chest, abdomen, and pelvis was carried out every 6 weeks until progressive disease (PD) was confirmed. Response was determined by the investigators according to RECIST 1.1. Adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Patients with PD after the study treatment were followed up every 3 months by telephone until death.
Zhang L., Wang W., Ge S., Li H., Bai M., Duan J., Yang Y., Ning T., Liu R., Wang X., Ji Z., Wang F., Zhang H., Ba Y, & Deng T. (2023). Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial. BMC Cancer, 23, 211.
Publication 2023
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl Abdomen Allergic Reaction Antiemetics apatinib Atropine BLOOD Chest Cholinergic Agents Cimetidine Clinical Protocols Combined Modality Therapy Condoms Dexamethasone Diphenhydramine Disease Progression Heart Hematologic Tests Immunomodulation Intravenous Infusion Irinotecan Paclitaxel Patients Pelvis Pharmaceutical Preparations Pharmacotherapy sintilimab Syndrome Thyroid Gland Urinalysis Urine X-Ray Computed Tomography

Top products related to «4-maleimido-2,2,6,6-tetramethylpiperidinooxyl»

1
4 maleimido tempo by Merck Group
Sourced in United States
4-maleimido-TEMPO is a spin label reagent used for the covalent attachment of a TEMPO (2,2,6,6-tetramethylpiperidine-1-oxyl) radical to biomolecules, such as proteins or peptides. It contains a maleimide functional group that can react with thiol groups, allowing the TEMPO moiety to be linked to target molecules.
2
Superdex 200 hr 10 30 column by Merck Group
Sourced in Germany
The Superdex 200 HR 10/30 column is a size-exclusion chromatography column used for the separation and purification of proteins, peptides, and other biomolecules. It is designed for high-resolution separations and has a separation range of 10,000 to 600,000 Da. The column is packed with a cross-linked agarose-dextran matrix and has a bed volume of 24 ml.
3
Protein g sepharose by Merck Group
Sourced in United States, Germany, Italy
Protein G Sepharose is a laboratory resin used for the purification of antibodies. It consists of Protein G, a bacterial cell wall protein that binds to the Fc region of immunoglobulins, immobilized on a cross-linked agarose matrix. This resin is commonly used to capture and isolate monoclonal and polyclonal antibodies from complex biological samples.
4
Gcrdvpms mrggdrcg vpm by GenScript
The GCRDVPMS↓MRGGDRCG (VPM) is a laboratory equipment product from GenScript. It is designed to perform a core function, but a detailed description without interpretation or extrapolation cannot be provided while maintaining an unbiased and factual approach.
5
4 amino tempo by Merck Group
Sourced in United States
4-Amino-TEMPO is a stable free radical compound used as a spin label and spin probe in electron paramagnetic resonance (EPR) spectroscopy. It is a nitroxide radical that can be attached to specific sites in biological macromolecules to study their structure and dynamics.
6
Spss version 18 by IBM
Sourced in United States, United Kingdom, Japan, Thailand, China, Italy, Germany
SPSS version 18.0 is a statistical software package developed by IBM. It provides data management, analysis, and reporting capabilities. The core function of SPSS is to assist in the analysis of data and presentation of results.
7
Neolsd by PerkinElmer
Sourced in Finland
NEOLSD is a laboratory instrument designed for high-performance liquid chromatography (HPLC) analysis. It provides reliable and accurate separation and detection of a wide range of compounds. The core function of NEOLSD is to facilitate the chromatographic analysis of samples in a laboratory setting.
8
Skyscan 1076 by Bruker
Sourced in Belgium, United States, Germany
The SkyScan 1076 is a high-resolution in vivo micro-CT scanner designed for small animal imaging. It provides non-invasive, three-dimensional imaging of the internal structure of small samples with a high level of detail.
9
2 4 6 trinitrobenzenesulfonic acid by Merck Group
Sourced in United States, Italy, Sao Tome and Principe
2,4,6-trinitrobenzenesulfonic acid is a chemical compound used in various laboratory applications. It serves as a reagent for the detection and quantification of primary amines. The compound exhibits high reactivity and is commonly employed in analytical procedures.
10
Nephelometric method by Beckman Coulter
Sourced in United States
The Nephelometric method is a laboratory technique used to measure the concentration of particles in a liquid sample. It works by detecting the amount of light scattered by the particles in the sample, which is proportional to the particle concentration. The method is commonly used to analyze the turbidity or cloudiness of solutions.

More about "4-maleimido-2,2,6,6-tetramethylpiperidinooxyl"

Exploring the Power of 4-Maleimido-2,2,6,6-Tetramethylpiperidinooxyl: Enhancing Your Research with AI-Driven Insights 4-Maleimido-2,2,6,6-tetramethylpiperidinooxyl (4-maleimido-TEMPO) is a versatile spin label widely used in various research applications, particularly in the fields of biochemistry, biophysics, and material science.
This nitroxide radical compound is known for its ability to provide valuable information about molecular structures, dynamics, and interactions through techniques like electron paramagnetic resonance (EPR) spectroscopy.
Beyond 4-maleimido-TEMPO, researchers often employ other related compounds and tools to investigate complex systems.
For instance, Superdex 200 HR 10/30 column is a size-exclusion chromatography resin commonly used for the purification and analysis of proteins and macromolecular complexes.
Similarly, Protein G Sepharose is a popular affinity chromatography medium utilized for the purification of antibodies and immunoglobulins.
To further explore the intricacies of biomolecular interactions, researchers may employ peptide sequences like GCRDVPMS↓MRGGDRCG (VPM), which can provide insights into protease activity and substrate specificity.
Additionally, compounds such as 4-Amino-TEMPO and its derivatives can serve as spin labels for the study of membrane-bound proteins and lipid environments.
The analysis of these complex systems often involves the use of statistical software, such as SPSS version 18.0, which enables researchers to perform advanced data analysis and interpretation.
Furthermore, techniques like NEOLSD and SkyScan 1076 (micro-CT) can be utilized to obtain high-resolution structural information and visualize the morphological characteristics of various samples.
To ensure the reliability and reproducibility of research findings, it is crucial to carefully evaluate experimental protocols and methods.
In this context, the use of 2,4,6-trinitrobenzenesulfonic acid and Nephelometric method can provide valuable insights into the purity, concentration, and aggregation state of biomolecules.
By leveraging the power of AI-driven platforms like PubCompare.ai, researchers can effortlessly locate the best protocols, products, and preprints related to 4-maleimido-2,2,6,6-tetramethylpiperidinooxyl and its associated research tools.
This platform empowers researchers to identify the most reliable and effective methods, saving time and enhancing the success of their experiments.
Experince the future of research with PubCompare.ai and unlock new possibilities in your scientific endeavors.